The concern of generic challenges has consistently loomed over copyright’s blockbuster drug, Viagra, raising questions about the outlook of connected pharmaceutical holdings. While initial periods saw substantial gains, the exclusivity end has allowed the path for less expensive copies, potentially reducing revenue and creating a genuine risk for